IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL5.21▼ 0.01% USD/MXN17.02▼ 0.01% USD/CLP914.45▼ 0.02% USD/COP3,141▲ 0.56% USD/PEN3.37▼ 0.01% USD/ARS1,488— 0.00% USD/UYU40.33▲ 1.98% USD/PYG5,984▲ 2.22% USD/BOB11.54▼ 0.18% USD/DOP58.45▲ 0.26% USD/CRC446.12▲ 2.03% USD/GTQ7.62▲ 2.25% USD/HNL26.79▲ 1.50% USD/NIO36.62— 0.00% USD/VES769.14▼ 0.32% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.70▲ 0.66% EUR/BRL6.05▲ 1.03% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 166,934.20 ▼ 0.10% IPSA 11,042.67 ▲ 0.39% IPC MEX 64,397.45 ▼ 0.66% MERVAL 2,947,349 ▼ 1.77% COLCAP 2,452.46 ▲ 0.84% BVL PERÚ 58,104.31 ▲ 0.40% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, August 16, 2026

Brazil May Authorize Chloroquine for Critical Covid-19 Patients; Flu Vaccinations Begin

By · March 23, 2020 · 3 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – The Ministry of Health may authorize, until Tuesday, March 24th, the prescription of chloroquine and hydroxychloroquine for severe Covid-19 cases, a disease caused by the novel coronavirus.

The statement was made earlier by the portfolio’s executive secretary, João Gabbardo dos Reis. Until then, the ministry will release a note with guidelines on the use of the drugs.

In recent days, a study conducted in France was released in which chloroquine - used to treat malaria - and hydroxychloroquine - prescribed for cases of rheumatoid arthritis and lupus - decreased the viral count.
In recent days, a study conducted in France was released in which chloroquine – used to treat malaria – and hydroxychloroquine – prescribed for cases of rheumatoid arthritis and lupus – decreased the viral count. (Photo: internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

However, the secretary stated that the potential release of the drugs will be experimental and will only apply to patients hospitalized in critical condition. He reiterated that the two components have strong side effects and cannot be stored to be used in potential flu cases.

“Today, [the drugs] are used in clinical research, with authorization from the hospitals’ ethics committees, in association with other drugs. If the Ministry of Health releases the prescription, it can be used for critically ill patients in hospitals. It’s not to be used by people who have the flu and who think that if they take this drug, they won’t have complications,” Gabbardo says.

In recent days, a study conducted in France was released in which chloroquine – used to treat malaria – and hydroxychloroquine – prescribed for cases of rheumatoid arthritis and lupus – decreased the viral count. On Friday, Match 20th, US President Donald Trump reported that the US government is studying the use of the drugs to treat the new coronavirus.

Regarding President Jair Bolsonaro’s authorization for the Army to increase drug production, the executive secretary said the measure was preventive in the event of a potential increase in future demand. In Brazil, the product is manufactured in private laboratories, the Armed Forces and the Oswaldo Cruz Foundation (Fiocruz).

“These drugs are already manufactured in Brazil and exist in pharmacies. Due to the potential use for severe cases of coronavirus, we are considering the need to increase production. This is what the President authorized: that the Army may increase the production of drugs,” he explained. He recalled that the National Health Surveillance Agency (ANVISA) has restricted the sale of drugs to those people with medical attestation that they have the three diseases now treated by the drugs: malaria, lupus, and rheumatoid arthritis.

The government of Pará will perform a drive-thru vaccination system in which the driver does not get out of the car.
The government of Pará will perform a drive-thru vaccination system in which the driver does not get out of the car. (Photo: internet reproduction)

Vaccination

Regarding the influenza vaccination campaign, which begins on Monday, March 23rd, for seniors and health professionals, Health Surveillance Secretary Wanderson Kleber de Oliveira reported initiatives by states and municipalities to prevent the crowding of seniors in health facilities. He mentioned partnerships with schools for vaccination in courtyards, better-ventilated environments, and agreements with drugstores, companies, and organizations in the productive sector to prevent the concentration of people in a single place.

Oliveira mentioned initiatives for health professionals to take the doses to hospital facilities and clinics for colleagues to be vaccinated. This, the secretary said, prevents the mass displacement of health professionals to vaccination posts. He further mentioned an initiative by the government of Pará, which will perform a drive-thru vaccination system in which the driver does not get out of the car.

The secretary reiterated the recommendation for local governments to defer vaccination of children. The campaign begins this Monday for the elderly and health professionals. In the subsequent stage, public safety professionals, the chronically ill and people with restricted freedom will be vaccinated. In its last stage, vaccination will only be available to the remaining people. He mentioned the streamlining of registration, collecting only the vaccine record, not the patient’s name, to reduce the length of stay in the facility.

Source: Exame

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.